FDA drops risk statements from boxed warnings of three estradiol patches; societies tie women's heart risk to life stages; iodine raises LEEP margins
Listen to this post
read by AI voices · all episodesThe Food and Drug Administration (FDA) on Oct. 30 approved removal of breast cancer, heart disease and dementia statements from boxed warnings on three more estradiol patches, the Department of Health and Human Services said.
The American Heart Association, the American College of Obstetricians and Gynecologists and two other groups published a female life-stage framework for cardiovascular prevention. A German trial found iodine staining raised involved margins after loop excision, and a New Zealand trial favored self-assessment after early medical abortion.
- FDA Oct 30, 2026The Food and Drug Administration (FDA) on Oct. 30 approved updated labels for three estradiol transdermal patches from two applicants, removing statements on cardiovascular disease, breast cancer and probable dementia from their boxed warnings, the Department of Health and Human Services said. The FDA earlier approved labeling changes for six menopausal hormone therapy products, and 29 companies have submitted proposed label changes. The agency said patch output has doubled in 12 months and it is not aware of an imminent risk of a nationwide shortage.
- Guidelines Oct 26, 2026The American Heart Association (AHA), American Academy of Pediatrics, American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine published three Circulation papers Oct. 26: a presidential advisory defining four life stages from perimenarche to postmenopause, a scientific statement with consensus guidance and a science advisory proposing Comprehensive Centers of Excellence for Women's Cardiovascular Care. The papers treat menstrual cycle patterns as a female-specific vital sign and call for 10- and 30-year sex-specific risk estimation with the PREVENT equations. Only about 60% of U.S. women with pregnancy-related hypertension complications get follow-up within six months, the AHA said.Sources: American Heart Association, Healio
- Research Oct 26, 2026In a randomized trial of 229 women at a university colposcopy unit in Bochum, Germany, published Oct. 26 in the American Journal of Obstetrics & Gynecology, loop electrosurgical excision with intraoperative Lugol's iodine staining produced involved resection margins in 17.5% of women versus 7.0% without iodine (risk ratio 2.52; 95% CI 1.16 to 5.49; P = .014), the primary end point. Bleeding in the first 24 hours was lower with iodine, and pain and satisfaction did not differ. The authors said iodine staining should not be used routinely.
- Research Oct 25, 2026In the Mate Whenua randomized trial at six abortion services in New Zealand, published Oct. 25 in BJOG, self-assessment with a low-sensitivity urine pregnancy test after early medical abortion produced complete follow-up in 94.5% of participants versus 67.4% with serial serum beta-hCG testing (relative risk 1.41; 95% CI 1.30 to 1.52; P < .001), the primary end point. Complications did not differ (8.5% versus 8.7%). One ongoing live pregnancy was detected after the first trimester among 732 participants.
The weekly innovation roundup for obstetrics and gynecology, published every Sunday for the week before; every item links to its sources. Latest obstetrics and gynecology news · All specialties